# EDGAR Filing Document

**Accession Number:** 0001832106
**File Stem:** 0000919574-25-007332
**Filing Date:** 2025-12
**Character Count:** 42218
**Document Hash:** 0306531ca7f89bdc5fe2e21ab0ba38cf
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000919574-25-007332.hdr.sgml**: 20251211

**ACCESSION NUMBER**: 0000919574-25-007332

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13G/A

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20251211

**DATE AS OF CHANGE**: 20251211

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Ceribell, Inc.
- **CENTRAL INDEX KEY:** 0001861107
- **STANDARD INDUSTRIAL CLASSIFICATION:** ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 471785452
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13G/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-94656
- **FILM NUMBER:** 251564685

**BUSINESS ADDRESS:**
- **STREET 1:** 360 N. PASTORIA AVENUE
- **CITY:** SUNNYVALE
- **STATE:** CA
- **ZIP:** 94085
- **BUSINESS PHONE:** (800) 436-0826

**MAIL ADDRESS:**
- **STREET 1:** 360 N. PASTORIA AVENUE
- **CITY:** SUNNYVALE
- **STATE:** CA
- **ZIP:** 94085
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ABG Management Ltd.
- **CENTRAL INDEX KEY:** 0001832106

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13G/A

**BUSINESS ADDRESS:**
- **STREET 1:** 15 QUEENS ROAD CENTRAL, UNIT 3002-3004
- **STREET 2:** 30TH FLOOR, GLOUCESTER TWR, THE LANDMARK
- **CITY:** HONG KONG
- **STATE:** F4
- **ZIP:** 0000000000
- **BUSINESS PHONE:** 852 31219699

**MAIL ADDRESS:**
- **STREET 1:** 15 QUEENS ROAD CENTRAL, UNIT 3002-3004
- **STREET 2:** 30TH FLOOR, GLOUCESTER TWR, THE LANDMARK
- **CITY:** HONG KONG
- **STATE:** F4
- **ZIP:** 0000000000

## Ex-99

**Exhibit 1**

JOINT FILING AGREEMENT

The undersigned agree that this Schedule 13G dated December 11, 2025 relating to the Common Stock, $0.001 par value per share, of Ceribell, Inc. shall be filed on behalf of the undersigned.

IN WITNESS WHEREOF, the undersigned hereby execute this Agreement as of December 11, 2025.

---

| | | |
|:---|:---|:---|
| **ABG WTT-Ceribell Limited** | **ABG WTT-Ceribell Limited** | **ABG WTT-Ceribell Limited** |
| By: | /s/ Kevin Reilly | /s/ Kevin Reilly |
|  | Name: | /s/Kevin Reilly |
|  | Title: | Director |
| &nbsp;&nbsp;**ABG V-Ceribell Limited** | &nbsp;&nbsp;**ABG V-Ceribell Limited** | &nbsp;&nbsp;**ABG V-Ceribell Limited** |
| &nbsp;&nbsp;By: | &nbsp;&nbsp;/s/ Kevin Reilly | &nbsp;&nbsp;/s/ Kevin Reilly |
|  | &nbsp;&nbsp;Name: | &nbsp;&nbsp;Kevin Reilly |
|  | &nbsp;&nbsp;Title: | &nbsp;&nbsp;Director |
| &nbsp;&nbsp;**Ally Bridge Group Global Life Science Capital Partners V, L.P.** | &nbsp;&nbsp;**Ally Bridge Group Global Life Science Capital Partners V, L.P.** | &nbsp;&nbsp;**Ally Bridge Group Global Life Science Capital Partners V, L.P.** |
| &nbsp;&nbsp;By: ABG Global Life Science Capital Partners V GP, L.P., its general partner | &nbsp;&nbsp;By: ABG Global Life Science Capital Partners V GP, L.P., its general partner | &nbsp;&nbsp;By: ABG Global Life Science Capital Partners V GP, L.P., its general partner |
| &nbsp;&nbsp;By: ABG Global Life Science Capital Partners V GP Limited, its general partner | &nbsp;&nbsp;By: ABG Global Life Science Capital Partners V GP Limited, its general partner | &nbsp;&nbsp;By: ABG Global Life Science Capital Partners V GP Limited, its general partner |
| &nbsp;&nbsp;By: | &nbsp;&nbsp;/s/ Fan Yu | &nbsp;&nbsp;/s/ Fan Yu |
|  | &nbsp;&nbsp;Name: | &nbsp;&nbsp;Fan Yu |
|  | &nbsp;&nbsp;Title: | &nbsp;&nbsp;Director |
| &nbsp;&nbsp;**ABG Global Life Science Capital Partners V GP, L.P.** | &nbsp;&nbsp;**ABG Global Life Science Capital Partners V GP, L.P.** | &nbsp;&nbsp;**ABG Global Life Science Capital Partners V GP, L.P.** |
| &nbsp;&nbsp;By: ABG Global Life Science Capital Partners V GP Limited, its general partner | &nbsp;&nbsp;By: ABG Global Life Science Capital Partners V GP Limited, its general partner | &nbsp;&nbsp;By: ABG Global Life Science Capital Partners V GP Limited, its general partner |
| &nbsp;&nbsp;By: | &nbsp;&nbsp;/s/ Fan Yu | &nbsp;&nbsp;/s/ Fan Yu |
|  | &nbsp;&nbsp;Name: | &nbsp;&nbsp;Fan Yu |
|  | &nbsp;&nbsp;Title: | &nbsp;&nbsp;Director |
| **ABG Global Life Science Capital Partners V GP Limited** | **ABG Global Life Science Capital Partners V GP Limited** | **ABG Global Life Science Capital Partners V GP Limited** |
| By: | /s/ Fan Yu | /s/ Fan Yu |
|  | Name: | Fan Yu |
|  | Title: | Director |

---

---

| | | |
|:---|:---|:---|
| **Ally Bridge Group-WTT Global Life Science Capital Partners, L.P.** | **Ally Bridge Group-WTT Global Life Science Capital Partners, L.P.** | **Ally Bridge Group-WTT Global Life Science Capital Partners, L.P.** |
| By: ABG-WTT Global Life Science Capital Partners GP, L.P., its general partner | By: ABG-WTT Global Life Science Capital Partners GP, L.P., its general partner | By: ABG-WTT Global Life Science Capital Partners GP, L.P., its general partner |
| By: ABG-WTT Global Life Science Capital Partners GP Limited, its general partner | By: ABG-WTT Global Life Science Capital Partners GP Limited, its general partner | By: ABG-WTT Global Life Science Capital Partners GP Limited, its general partner |
| By: | /s/ Fan Yu | /s/ Fan Yu |
|  | Name: | Fan Yu |
|  | Title: | Director |
| **ABG-WTT Global Life Science Capital Partners GP, L.P.** | **ABG-WTT Global Life Science Capital Partners GP, L.P.** | **ABG-WTT Global Life Science Capital Partners GP, L.P.** |
| By: ABG-WTT Global Life Science Capital Partners GP Limited, its general partner | By: ABG-WTT Global Life Science Capital Partners GP Limited, its general partner | By: ABG-WTT Global Life Science Capital Partners GP Limited, its general partner |
| By: | /s/ Fan Yu | /s/ Fan Yu |
|  | Name: | Fan Yu |
|  | Title: | Director |

---

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;**ABG-WTT Global Life Science Capital Partners GP Limited** | &nbsp;&nbsp;**ABG-WTT Global Life Science Capital Partners GP Limited** | &nbsp;&nbsp;**ABG-WTT Global Life Science Capital Partners GP Limited** |
| &nbsp;&nbsp;By: | &nbsp;&nbsp;/s/ Fan Yu | &nbsp;&nbsp;/s/ Fan Yu |
|  | &nbsp;&nbsp;Name: | &nbsp;&nbsp;Fan Yu |
|  | &nbsp;&nbsp;Title: | &nbsp;&nbsp;Director |

---

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp; <br> **ABG-WTT Global Life Science Capital Partners GP, L.P.** | &nbsp;&nbsp; <br> **ABG-WTT Global Life Science Capital Partners GP, L.P.** | &nbsp;&nbsp; <br> **ABG-WTT Global Life Science Capital Partners GP, L.P.** |
| &nbsp;&nbsp;By: ABG-WTT Global Life Science Capital Partners GP Limited, its general partner | &nbsp;&nbsp;By: ABG-WTT Global Life Science Capital Partners GP Limited, its general partner | &nbsp;&nbsp;By: ABG-WTT Global Life Science Capital Partners GP Limited, its general partner |
| &nbsp;&nbsp;By: | &nbsp;&nbsp;/s/ Fan Yu | &nbsp;&nbsp;/s/ Fan Yu |
|  | &nbsp;&nbsp;Name: | &nbsp;&nbsp;Fan Yu |
|  | &nbsp;&nbsp;Title: | &nbsp;&nbsp;Director |
| &nbsp;&nbsp;**ABG-WTT Global Life Science Capital Partners GP Limited** | &nbsp;&nbsp;**ABG-WTT Global Life Science Capital Partners GP Limited** | &nbsp;&nbsp;**ABG-WTT Global Life Science Capital Partners GP Limited** |
| &nbsp;&nbsp;By: | &nbsp;&nbsp;/s/ Fan Yu | &nbsp;&nbsp;/s/ Fan Yu |
|  | &nbsp;&nbsp;Name: | &nbsp;&nbsp;Fan Yu |
|  | &nbsp;&nbsp;Title: | &nbsp;&nbsp;Director |
| &nbsp;&nbsp;**ABG Management Ltd.** | &nbsp;&nbsp;**ABG Management Ltd.** | &nbsp;&nbsp;**ABG Management Ltd.** |
| &nbsp;&nbsp; By:  | &nbsp;&nbsp;/s/ Fan Yu | &nbsp;&nbsp;/s/ Fan Yu |
|  | &nbsp;&nbsp;Name: | &nbsp;&nbsp;Fan Yu |
|  | &nbsp;&nbsp;Title: | &nbsp;&nbsp;Director |
| &nbsp;&nbsp;**Ally Bridge Group (PE) LLC** | &nbsp;&nbsp;**Ally Bridge Group (PE) LLC** | &nbsp;&nbsp;**Ally Bridge Group (PE) LLC** |
| &nbsp;&nbsp;By: ABG Management Ltd., its managing member | &nbsp;&nbsp;By: ABG Management Ltd., its managing member | &nbsp;&nbsp;By: ABG Management Ltd., its managing member |
| &nbsp;&nbsp; By:  | &nbsp;&nbsp;/s/ Fan Yu | &nbsp;&nbsp;/s/ Fan Yu |
|  | &nbsp;&nbsp;Name: | &nbsp;&nbsp;Fan Yu |
|  | &nbsp;&nbsp;Title: | &nbsp;&nbsp;Director |
| &nbsp;&nbsp;**Fan Yu** | &nbsp;&nbsp;**Fan Yu** | &nbsp;&nbsp;**Fan Yu** |
| &nbsp;&nbsp;By: | &nbsp;&nbsp;/s/ Fan Yu | &nbsp;&nbsp;/s/ Fan Yu |
|  | &nbsp;&nbsp;Name: | &nbsp;&nbsp;Fan Yu |

---

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13G

### Under the Securities Exchange Act of 1934

**(Amendment No. 1)**

**Issuer:** Ceribell, Inc.

**Title of Class of Securities:** Common Stock, $0.001 par value per share

**CUSIP Number:** 15678C102

**Date of Event Which Requires Filing of this Statement:** 12/09/2024

**Check the appropriate box to designate the rule pursuant to which this Schedule is filed:**

- [ ] Rule 13d-1(b)

- [x] Rule 13d-1(c)

- [ ] Rule 13d-1(d)

---

| 1. | Names of Reporting Persons<br>ABG WTT-Ceribell Limited | Names of Reporting Persons<br>ABG WTT-Ceribell Limited |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [x] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [x] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>E9 | Citizenship or Place of Organization<br>E9 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>1691267.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>1691267.00 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>1691267.00 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>1691267.00 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>4.6% | Percent of Class Represented by Amount in Row (9)<br>4.6% |
| 12. | Type of Reporting Person (See Instructions)<br>OO | Type of Reporting Person (See Instructions)<br>OO |

**Comment for Type of Reporting Person:** The percentage of ownership based on 37,095,690 shares of Common Stock of the Issuer outstanding as of October 31, 2025, as reported on the Issuer's Form 10-Q filed on November 4, 2025.

---

| 1. | Names of Reporting Persons<br>ABG V-Ceribell Limited | Names of Reporting Persons<br>ABG V-Ceribell Limited |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [x] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [x] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>E9 | Citizenship or Place of Organization<br>E9 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>1691267.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>1691267.00 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>1691267.00 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>1691267.00 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>4.6% | Percent of Class Represented by Amount in Row (9)<br>4.6% |
| 12. | Type of Reporting Person (See Instructions)<br>CO | Type of Reporting Person (See Instructions)<br>CO |

**Comment for Type of Reporting Person:** ABG V-Ceribell Limited is in a position to, directly or indirectly, exercise or share the ultimate voting and disposition control of the Common Stock owned by ABG WTT-Ceribell Limited.

The percentage of ownership based on 37,095,690 shares of Common Stock of the Issuer outstanding as of October 31, 2025, as reported on the Issuer's Form 10-Q filed on November 4, 2025.

---

| 1. | Names of Reporting Persons<br>Ally Bridge Group Global Life Science Capital Partners V, L.P. | Names of Reporting Persons<br>Ally Bridge Group Global Life Science Capital Partners V, L.P. |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [x] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [x] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>E9 | Citizenship or Place of Organization<br>E9 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>1691267.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>1691267.00 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>1691267.00 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>1691267.00 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>4.6% | Percent of Class Represented by Amount in Row (9)<br>4.6% |
| 12. | Type of Reporting Person (See Instructions)<br>PN | Type of Reporting Person (See Instructions)<br>PN |

**Comment for Type of Reporting Person:** Ally Bridge Group Global Life Science Capital Partners V, L.P. is in a position to, directly or indirectly, exercise or share the ultimate voting and disposition control of the Common Stock owned by ABG WTT-Ceribell Limited.

The percentage of ownership based on 37,095,690 shares of Common Stock of the Issuer outstanding as of October 31, 2025, as reported on the Issuer's Form 10-Q filed on November 4, 2025.

---

| 1. | Names of Reporting Persons<br>ABG Global Life Science Capital Partners V GP, L.P. | Names of Reporting Persons<br>ABG Global Life Science Capital Partners V GP, L.P. |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [x] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [x] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>E9 | Citizenship or Place of Organization<br>E9 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>1691267.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>1691267.00 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>1691267.00 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>1691267.00 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>4.6% | Percent of Class Represented by Amount in Row (9)<br>4.6% |
| 12. | Type of Reporting Person (See Instructions)<br>PN | Type of Reporting Person (See Instructions)<br>PN |

**Comment for Type of Reporting Person:** ABG Global Life Science Capital Partners V GP, L.P. is in a position to, directly or indirectly, exercise or share the ultimate voting and disposition control of the Common Stock owned by ABG WTT-Ceribell Limited.

 The percentage of ownership based on 37,095,690 shares of Common Stock of the Issuer outstanding as of October 31, 2025, as reported on the Issuer's Form 10-Q filed on November 4, 2025.

---

| 1. | Names of Reporting Persons<br>ABG Global Life Science Capital Partners V GP Limited | Names of Reporting Persons<br>ABG Global Life Science Capital Partners V GP Limited |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [x] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [x] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>E9 | Citizenship or Place of Organization<br>E9 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>1691267.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>1691267.00 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>1691267.00 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>1691267.00 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>4.6% | Percent of Class Represented by Amount in Row (9)<br>4.6% |
| 12. | Type of Reporting Person (See Instructions)<br>CO | Type of Reporting Person (See Instructions)<br>CO |

**Comment for Type of Reporting Person:** ABG Global Life Science Capital Partners V GP Limited is in a position to, directly or indirectly, exercise or share the ultimate voting and disposition control of the Common Stock owned by ABG WTT-Ceribell Limited.

The percentage of ownership based on 37,095,690 shares of Common Stock of the Issuer outstanding as of October 31, 2025, as reported on the Issuer's Form 10-Q filed on November 4, 2025.

---

| 1. | Names of Reporting Persons<br>Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. | Names of Reporting Persons<br>Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [x] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [x] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>E9 | Citizenship or Place of Organization<br>E9 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>1691267.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>1691267.00 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>1691267.00 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>1691267.00 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>4.6% | Percent of Class Represented by Amount in Row (9)<br>4.6% |
| 12. | Type of Reporting Person (See Instructions)<br>PN | Type of Reporting Person (See Instructions)<br>PN |

**Comment for Type of Reporting Person:** Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. is in a position to, directly or indirectly, exercise or share the ultimate voting and disposition control of the Common Stock owned by ABG WTT-Ceribell Limited.

The percentage of ownership based on 37,095,690 shares of Common Stock of the Issuer outstanding as of October 31, 2025, as reported on the Issuer's Form 10-Q filed on November 4, 2025.

---

| 1. | Names of Reporting Persons<br>ABG-WTT Global Life Science Capital Partners GP, L.P. | Names of Reporting Persons<br>ABG-WTT Global Life Science Capital Partners GP, L.P. |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [x] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [x] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>E9 | Citizenship or Place of Organization<br>E9 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>1691267.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>1691267.00 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>1691267.00 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>1691267.00 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>4.6% | Percent of Class Represented by Amount in Row (9)<br>4.6% |
| 12. | Type of Reporting Person (See Instructions)<br>PN | Type of Reporting Person (See Instructions)<br>PN |

**Comment for Type of Reporting Person:** ABG-WTT Global Life Science Capital Partners GP, L.P. is in a position to, directly or indirectly, exercise or share the ultimate voting and disposition control of the Common Stock owned by ABG WTT-Ceribell Limited.

The percentage of ownership based on 37,095,690 shares of Common Stock of the Issuer outstanding as of October 31, 2025, as reported on the Issuer's Form 10-Q filed on November 4, 2025.

---

| 1. | Names of Reporting Persons<br>ABG-WTT Global Life Science Capital Partners GP Limited | Names of Reporting Persons<br>ABG-WTT Global Life Science Capital Partners GP Limited |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [x] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [x] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>E9 | Citizenship or Place of Organization<br>E9 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>1691267.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>1691267.00 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>1691267.00 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>1691267.00 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>4.6% | Percent of Class Represented by Amount in Row (9)<br>4.6% |
| 12. | Type of Reporting Person (See Instructions)<br>CO | Type of Reporting Person (See Instructions)<br>CO |

**Comment for Type of Reporting Person:** ABG-WTT Global Life Science Capital Partners GP Limited is in a position to, directly or indirectly, exercise or share the ultimate voting and disposition control of the Common Stock owned by ABG WTT-Ceribell Limited.

The percentage of ownership based on 37,095,690 shares of Common Stock of the Issuer outstanding as of October 31, 2025, as reported on the Issuer's Form 10-Q filed on November 4, 2025.

---

| 1. | Names of Reporting Persons<br>ABG Management Ltd. | Names of Reporting Persons<br>ABG Management Ltd. |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [x] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [x] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>E9 | Citizenship or Place of Organization<br>E9 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>1691267.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>1691267.00 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>1691267.00 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>1691267.00 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>4.6% | Percent of Class Represented by Amount in Row (9)<br>4.6% |
| 12. | Type of Reporting Person (See Instructions)<br>CO | Type of Reporting Person (See Instructions)<br>CO |

**Comment for Type of Reporting Person:** ABG Management Ltd. is in a position to, directly or indirectly, exercise or share the ultimate voting and disposition control of the Common Stock owned by ABG WTT-Ceribell Limited.

The percentage of ownership based on 37,095,690 shares of Common Stock of the Issuer outstanding as of October 31, 2025, as reported on the Issuer's Form 10-Q filed on November 4, 2025

---

| 1. | Names of Reporting Persons<br>Ally Bridge Group (PE) LLC | Names of Reporting Persons<br>Ally Bridge Group (PE) LLC |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [x] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [x] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>DE | Citizenship or Place of Organization<br>DE |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>1691267.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>1691267.00 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>1691267.00 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>1691267.00 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>4.6% | Percent of Class Represented by Amount in Row (9)<br>4.6% |
| 12. | Type of Reporting Person (See Instructions)<br>IA, OO | Type of Reporting Person (See Instructions)<br>IA, OO |

**Comment for Type of Reporting Person:** Ally Bridge Group (PE) LLC is in a position to, directly or indirectly, exercise or share the ultimate voting and disposition control of the Common Stock owned by ABG WTT-Ceribell Limited.

The percentage of ownership based on 37,095,690 shares of Common Stock of the Issuer outstanding as of October 31, 2025, as reported on the Issuer's Form 10-Q filed on November 4, 2025.

---

| 1. | Names of Reporting Persons<br>Fan Yu | Names of Reporting Persons<br>Fan Yu |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [x] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [x] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>O1 | Citizenship or Place of Organization<br>O1 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>1691267.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>1691267.00 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>1691267.00 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>1691267.00 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>4.6% | Percent of Class Represented by Amount in Row (9)<br>4.6% |
| 12. | Type of Reporting Person (See Instructions)<br>IN | Type of Reporting Person (See Instructions)<br>IN |

**Comment for Type of Reporting Person:** Fan Yu is in a position to, directly or indirectly, exercise or share the ultimate voting and disposition control of the Common Stock owned by ABG WTT-Ceribell Limited.

The percentage of ownership based on 37,095,690 shares of Common Stock of the Issuer outstanding as of October 31, 2025, as reported on the Issuer's Form 10-Q filed on November 4, 2025.

---

**Item 1(a). Name of Issuer:**
Ceribell, Inc.

**Item 1(b). Address of Issuer's Principal Executive Offices:**
360 N. Pastoria Avenue, Sunnyvale, California 94085

**Item 2(a). Name of Person Filing:**
ABG WTT-Ceribell Limited
ABG V-Ceribell Limited
Ally Bridge Group Global Life Science Capital Partners V, L.P.
ABG Global Life Science Capital Partners V GP, L.P.
ABG Global Life Science Capital Partners V GP Limited
Ally Bridge Group-WTT Global Life Science Capital Partners, L.P.
ABG-WTT Global Life Science Capital Partners GP, L.P.
ABG-WTT Global Life Science Capital Partners GP Limited
ABG Management Ltd.
Ally Bridge Group (PE) LLC
Fan Yu

**Item 2(b). Address of Principal Business Office:**
ABG WTT-Ceribell Limitedc/o Maples Corporate Services Limited
Ugland House, Grand Cayman
Cayman Islands
KY1-1104

ABG V-Ceribell Limitedc/o Maples Corporate Services Limited
Ugland House, Grand Cayman
Cayman Islands
KY1-1104

Ally Bridge Group Global Life Science Capital Partners V, L.P.c/o Maples Corporate Services Limited
Ugland House, Grand Cayman
Cayman Islands
KY1-1104

ABG Global Life Science Capital Partners V GP, L.P.c/o Maples Corporate Services Limited
Ugland House, Grand Cayman
Cayman Islands
KY1-1104

ABG Global Life Science Capital Partners V GP Limitedc/o Maples Corporate Services Limited
Ugland House, Grand Cayman
Cayman Islands
KY1-1104

Ally Bridge Group-WTT Global Life Science Capital Partners, L.P.c/o Maples Corporate Services Limited
Ugland House, Grand Cayman
Cayman Islands
KY1-1104

ABG-WTT Global Life Science Capital Partners GP, L.P.c/o Maples Corporate Services Limited
Ugland House, Grand Cayman
Cayman Islands
KY1-1104

ABG-WTT Global Life Science Capital Partners GP Limitedc/o Maples Corporate Services Limited
Ugland House, Grand Cayman
Cayman Islands
KY1-1104

ABG Management Ltd.c/o Maples Corporate Services Limited
Ugland House, Grand Cayman
Cayman Islands
KY1-1104

Ally Bridge Group (PE) LLC
430 Park Avenue
New York, New York 10022
United States of America

Fan Yuc/o Maples Corporate Services Limited
Ugland House, Grand Cayman
Cayman Islands
KY1-1104

**Item 2(c). Citizenship:**
ABG WTT-Ceribell Limited - Cayman Islands
ABG V-Ceribell Limited - Cayman Islands
Ally Bridge Group Global Life Science Capital Partners V, L.P. - Cayman Islands
ABG Global Life Science Capital Partners V GP, L.P. - Cayman Islands
ABG Global Life Science Capital Partners V GP Limited - Cayman Islands
Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. - Cayman Islands
ABG-WTT Global Life Science Capital Partners GP, L.P. - Cayman Islands
ABG-WTT Global Life Science Capital Partners GP Limited - Cayman Islands
ABG Management Ltd.- Cayman Islands
Ally Bridge Group (PE) LLC - Delaware
Fan Yu - Malta

**Item 2(d). Title of Class of Securities:**
Common Stock, $0.001 par value per share

**Item 2(e). CUSIP Number:**
15678C102

**Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:**

(a) [ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

(b) [ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

(c) [ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

(d) [ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

(e) [ ] An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f) [ ] An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g) [ ] A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h) [ ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i) [ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j) [ ] A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), if filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

(k) [ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

**Item 4. Ownership:**

**(a) Amount beneficially owned:**

ABG WTT-Ceribell Limited:  1,691,267
ABG V-Ceribell Limited:  1,691,267
Ally Bridge Group Global Life Science Capital Partners V, L.P.:  1,691,267
ABG Global Life Science Capital Partners V GP, L.P.:  1,691,267
ABG Global Life Science Capital Partners V GP Limited:  1,691,267
Ally Bridge Group-WTT Global Life Science Capital Partners, L.P.:  1,691,267
ABG-WTT Global Life Science Capital Partners GP, L.P.:   1,691,267
ABG-WTT Global Life Science Capital Partners GP Limited:   1,691,267
ABG Management Ltd.:   1,691,267
Ally Bridge Group (PE) LLC:  1,691,267
Fan Yu:   1,691,267

**(b) Percent of class:**

ABG WTT-Ceribell Limited: 4.6%
ABG V-Ceribell Limited: 4.6%
Ally Bridge Group Global Life Science Capital Partners V, L.P. : 4.6%
ABG Global Life Science Capital Partners V GP, L.P. : 4.6%
ABG Global Life Science Capital Partners V GP Limited: 4.6%
Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. : 4.6%
ABG-WTT Global Life Science Capital Partners GP, L.P.: 4.6%
ABG-WTT Global Life Science Capital Partners GP Limited: 4.6%
ABG Management Ltd.: 4.6%
Ally Bridge Group (PE) LLC: 4.6%
Fan Yu: 4.6%

**(c) Number of shares as to which the person has:**

**(i) Sole power to vote or to direct the vote:**

ABG WTT-Ceribell Limited: 0
ABG V-Ceribell Limited: 0
Ally Bridge Group Global Life Science Capital Partners V, L.P. : 0
ABG Global Life Science Capital Partners V GP, L.P. : 0
ABG Global Life Science Capital Partners V GP Limited: 0
Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. : 0
ABG-WTT Global Life Science Capital Partners GP, L.P.: 0
ABG-WTT Global Life Science Capital Partners GP Limited: 0
ABG Management Ltd.: 0
Ally Bridge Group (PE) LLC: 0
Fan Yu: 0

**(ii) Shared power to vote or to direct the vote:**

ABG WTT-Ceribell Limited: 1,691,267
ABG V-Ceribell Limited:   1,691,267
Ally Bridge Group Global Life Science Capital Partners V, L.P.:   1,691,267
ABG Global Life Science Capital Partners V GP, L.P.:   1,691,267
ABG Global Life Science Capital Partners V GP Limited:   1,691,267
Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. :   1,691,267
ABG-WTT Global Life Science Capital Partners GP, L.P.:   1,691,267
ABG-WTT Global Life Science Capital Partners GP Limited:   1,691,267
ABG Management Ltd.:   1,691,267
Ally Bridge Group (PE) LLC:   1,691,267
Fan Yu:   1,691,267

**(iii) Sole power to dispose or to direct the disposition of:**

ABG WTT-Ceribell Limited: 0
ABG V-Ceribell Limited: 0
Ally Bridge Group Global Life Science Capital Partners V, L.P. : 0
ABG Global Life Science Capital Partners V GP, L.P. : 0
ABG Global Life Science Capital Partners V GP Limited: 0
Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. : 0
ABG-WTT Global Life Science Capital Partners GP, L.P.: 0
ABG-WTT Global Life Science Capital Partners GP Limited: 0
ABG Management Ltd.: 0
Ally Bridge Group (PE) LLC: 0
Fan Yu: 0

**(iv) Shared power to dispose or to direct the disposition of:**

ABG WTT-Ceribell Limited: 1,691,267
ABG V-Ceribell Limited:   1,691,267
Ally Bridge Group Global Life Science Capital Partners V, L.P.:   1,691,267
ABG Global Life Science Capital Partners V GP, L.P.:   1,691,267
ABG Global Life Science Capital Partners V GP Limited:   1,691,267
Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. :   1,691,267
ABG-WTT Global Life Science Capital Partners GP, L.P.:   1,691,267
ABG-WTT Global Life Science Capital Partners GP Limited:   1,691,267
ABG Management Ltd.:   1,691,267
Ally Bridge Group (PE) LLC:   1,691,267
Fan Yu:   1,691,267

**Item 5. Ownership of Five Percent or Less of a Class.**

[ ] If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following.

**Item 6. Ownership of More than 5 Percent on Behalf of Another Person.**

Not Applicable

**Item 7. Identification and Classification of the Subsidiary**

Not Applicable

**Item 8. Identification and Classification of Members of the Group**

Not Applicable

**Item 9. Notice of Dissolution of Group**

Not Applicable

**Item 10. Certification:**

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**ABG WTT-Ceribell Limited**

**Date:** 12/11/2025

**By:** By: /s/ Kevin Reilly

**Name & Title:** Kevin Reilly, Director

**ABG V-Ceribell Limited**

**Date:** 12/11/2025

**By:** By: /s/ Kevin Reilly

**Name & Title:** Kevin Reilly, Director

**Ally Bridge Group Global Life Science Capital Partners V, L.P.**

**Date:** 12/11/2025

**By:** By: ABG Global Life Science Capital Partners V GP, L.P., its general partner, By: ABG Global Life Science Capital Partners V GP Limited, its general p

**Name & Title:** Fan Yu, Director

**ABG Global Life Science Capital Partners V GP, L.P.**

**Date:** 12/11/2025

**By:** By: ABG Global Life Science Capital Partners V GP Limited, its general partner, By: /s/ Fan Yu

**Name & Title:** Fan Yu, Director

**ABG Global Life Science Capital Partners V GP Limited**

**Date:** 12/11/2025

**By:** By: /s/ Fan Yu

**Name & Title:** Fan Yu, Director

**Ally Bridge Group-WTT Global Life Science Capital Partners, L.P.**

**Date:** 12/11/2025

**By:** By: ABG-WTT Global Life Science Capital Partners GP, L.P., its general partner, By: ABG-WTT Global Life Science Capital Partners GP Limited, its gener

**Name & Title:** Fan Yu, Director

**ABG-WTT Global Life Science Capital Partners GP, L.P.**

**Date:** 12/11/2025

**By:** By: ABG-WTT Global Life Science Capital Partners GP Limited, its general partner, By: /s/ Fan Yu

**Name & Title:** Fan Yu, Director

**ABG-WTT Global Life Science Capital Partners GP Limited**

**Date:** 12/11/2025

**By:** By: /s/ Fan Yu

**Name & Title:** Fan Yu, Director

**ABG Management Ltd.**

**Date:** 12/11/2025

**By:** By: /s/ Fan Yu

**Name & Title:** Fan Yu, Director

**Ally Bridge Group (PE) LLC**

**Date:** 12/11/2025

**By:** By: ABG Management Ltd., its managing member, By: /s/ Fan Yu

**Name & Title:** Fan Yu, Director

**Fan Yu**

**Date:** 12/11/2025

**By:** By: /s/ Fan Yu

**Name & Title:** Fan Yu